Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Cardiovasc Pathol ; 70: 107625, 2024.
Article in English | MEDLINE | ID: mdl-38417471

ABSTRACT

Erdheim-Chester disease (ECD) is a rare histiocytosis characterized by the foamy CD68+CD1a- histiocytes infiltrating multiple organs and tissues. ECD might be asymptomatic or present with variable manifestations. The diagnosis of ECD requires characteristic radiological findings and pathological features. Herein, we described a 52-year-old female patient who was admitted to our hospital for recurrent pericardial effusion for two months. She has a medical history of papillary thyroid carcinoma (PTC) and underwent a total thyroidectomy two years before admission. The radiological findings suggested a potential diagnosis of ECD. Cytological analysis of the effusion cytology specimen revealed CD68+CD1a- histiocytes, confirming the ECD diagnosis. The BRAF V600E mutation was identified in the histiocytes, prompting the administration of vemurafenib, a BRAF inhibitor. After two months of standard-dose vemurafenib treatment, the disease was well controlled with pericardial effusion regression.


Subject(s)
Erdheim-Chester Disease , Pericardial Effusion , Proto-Oncogene Proteins B-raf , Vemurafenib , Female , Humans , Middle Aged , Erdheim-Chester Disease/genetics , Erdheim-Chester Disease/drug therapy , Erdheim-Chester Disease/complications , Erdheim-Chester Disease/pathology , Erdheim-Chester Disease/diagnosis , Histiocytes/pathology , Mutation , Pericardial Effusion/pathology , Pericardial Effusion/etiology , Predictive Value of Tests , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins B-raf/genetics , Treatment Outcome , Vemurafenib/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL